Guggenheim analyst Subbu Nambi raised the firm’s price target on Personalis (PSNL) to $13 from $12 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Cathie Wood Doubles Down on High-Potential Biotech Plays
- NTLA, PSNL, KMTUY, ILMN: Cathie Wood Buys Early Biotech Stocks, Cuts Stakes in Illumina
- Personalis: Strengthened Balance Sheet and NeXT Personal Growth Underpin Reiterated Buy Rating and $12 Target
- Accelerating Clinical Adoption and Expanding Medicare Reimbursement Support Buy Rating and Favorable Risk-Reward Profile
- Personalis sees FY25 revenue $69M-$70M, consensus $69.96M